Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Ocumension Therapeutics
Company

Ocumension Therapeutics

Tracked across 1 events · 7 articles · First seen Feb 10, 2026 · Last active Feb 24, 2026

Sentiment
20
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 20
Business
NicOx NCX 470 Phase 3 Data Positive
Ocumension Therapeutics holds the license for NCX 470 in the Chinese, Korean, and Southeast Asian markets. The positive Phase 3 data for NCX 470 is beneficial for Ocumension Therapeutics as it moves closer to a New Drug Application in these regions.
Feb 10, 2026 · 7 articles
NEWSDESK
Track Ocumension Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.